The generic drug maker Mylan desires to put to rest the potential merger with Teva Pharmaceuticals which was highly speculated. Teva Pharmaceuticals is an acknowledged international pharmaceutical company which develops, manufactures, and market different generic and branded human medicines, active pharmaceutical ingredients, and medical disposables among others.
Mylan stated that the deal, despite being promising, lacks satisfactory industrial logic. The company emphasized that an adversity is likely to be met in the attempt to win the anti-trust clearances should the deal be pursued.
Also read: Tesla Posts Second Profitable Quarter Ever
16:36 AT&T, Time Warner poised to lobby lawmakers, regulators on proposed $85-billion merger23
12:23 Lockheed Martin's quarterly profit handily beats estimates20
11:41 Caterpillar earnings: 85 cents per share, vs expected EPS of 76 cents19
16:51 Scottrade Sale Nearly Doubles Owner’s Wealth to $4 Billion14